title: Quality of life and social isolation in Greek adolescents with primary focal hyperhidrosis treated with botulinum toxin type A: a case series.
abstract: Primary hyperhidrosis, although extensively documented in adults, typically has onset that dates back to early childhood. It is an unpleasant and socially disabling problem for the affected child, but little attention has been paid to the disease in adolescents. The objective of the current study was to evaluate the effectiveness of botulinum toxin type A (BTXA) in adolescents with primary palmar and axillary hyperhidrosis and to determine its effect on quality of life and social isolation. Thirty-five individuals (17 girls, 18 boys) with moderate to severe palmar and axillary hyperhidrosis were treated with BTXA (onabotulinum). Patients were examined at baseline and 6 months after treatment. The Hyperhidrosis Disease Severity Scale (HDSS) was used to evaluate disease severity and the Children's Dermatology Life Quality Index (CDLQI) was used to assess quality of life. The University of California at Los Angeles loneliness scale (UCLA version 3) was used to assess personal perception of loneliness and social isolation. The median age of the participants was 14 years, and 48.6% were female. Twenty-one had palmar hyperhidrosis, and 14 had axillary hyperhidrosis. Total CDLQI and social isolation scores decreased significantly after treatment with BTXA (both p < 0.001). There was a significant difference between pre- and post-treatment levels of severity of hyperhidrosis. No statistically significant difference was documented for CDLQI and UCLA scores between boys and girls. Treatment of hyperhidrosis with BTXA resulted in improvement in quality of life, social skills, and activities.
authors.affiliation: Department of Dermatology and Venereology, Andreas Sygros Hospital, Athens, Greece.
authors.forename: Anargyros
authors.initials: A
authors.lastname: Kouris
authors.forename: Kalliopi
authors.initials: K
authors.lastname: Armyra
authors.forename: Christina
authors.initials: C
authors.lastname: Stefanaki
authors.forename: Christos
authors.initials: C
authors.lastname: Christodoulou
authors.forename: Polixeni
authors.initials: P
authors.lastname: Karimali
authors.forename: George
authors.initials: G
authors.lastname: Kontochristopoulos
mesh_terms: D000293:Adolescent; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006115:Greece; D006801:Humans; D006945:Hyperhidrosis / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology*; D008297:Male; D011446:Prospective Studies; D011788:Quality of Life; D012720:Severity of Illness Index; D012934:Social Isolation / Q000523:psychology*; D013315:Stress, Psychological; D016896:Treatment Outcome
chemical_list: D019274:Botulinum Toxins, Type A